Ann: Azer-cel Hits Major Milestone in Phase 1b CAR T Trial, page-124

Hi dear Owl

Yes indeed!

Many here - including yourself - have commented on how focussed and efficient IMU is with their clinical trials. That's also something Yuman Fong emphasised in his investor presentations earlier this year. So I was expecting them to be pretty effective with the progression of Azer-Cel, but I must admit I am amazed at just how fast they have moved to get this Phase 1b going. First patient dosed already! That really is a zinger.

It was a brilliant acquisition - despite the CR - and Imugene is now moving very rapidly indeed. The prospect of combining Azer-Cel with Oncarlytics is incredibly exciting, but yeah - IMU may just end up with the world's first approved Allogenic CAR-T. On its own, Azer-Cel could be a blockbuster, and transform the lives of people living with Non Hodgkins Lymphoma, with many other possible indications down the track.

This makes my first day home after our holiday as good as the holiday itself! Today's share price action is fun to watch, of course, but the real excitement is the science, and the potential for how far Imugene can go with that.

It really is an incredible journey, and the best is yet to come.

Cheers

Dave